Sign in Subscribe
Pharmaceutical industry

GastroPlus Simulation Software to Model Drug Absorption Rates in Human Gastro-Intestinal Tract

Strategic Insights

— 1 min read

Simulations Plus, Inc., a provider of pharmaceutical development software, has announced that Parke-Davis, a Division of Warner-Lambert, has signed a Beta test agreement for their new GastroPlus simulation software. GastroPlus predicts the percentage of a drug material taken orally that will be absorbed through the gastro-intestinal tract into the portal vein. The software includes an advanced mathematical model that accounts for pH-dependent dissolution of drug material, controlled release profiles, and stochastic simulation capabilities. The agreement does not obligate Parke-Davis to license the software, and the production version of GastroPlus is expected to be released around March 1.

Key Takeaways:

  • GastroPlus simulation software models drug absorption rates in the human gastro-intestinal tract.
  • The software includes an advanced mathematical model developed by Therapeutic Systems Research Laboratories, accounting for pH-dependent dissolution of drug material, controlled release profiles, and stochastic simulation capabilities.
  • The agreement between Simulations Plus and Parke-Davis involves a three-week Beta test, with release of the production version expected around March 1.
  • The production version of GastroPlus will be available for licensing at a reduced fee compared to the usual license price.
  • Parke-Davis will provide feedback to Simulations Plus regarding the program, and will have the option to license the software at a reduced fee.
  • Simulations Plus estimates that GastroPlus has a worldwide potential customer base of thousands of biotech and pharmaceutical companies.
  • The software is expected to save time and money in both the drug discovery and development phases.

Statistics:

  • The gastro-intestinal tract absorbs approximately 10-20% of orally administered drugs.
  • The production version of GastroPlus is expected to be released around March 1, 1998.
  • The number of biotech and pharmaceutical companies that may be potential customers for GastroPlus is estimated to be thousands worldwide.
  • Simulations Plus has a staff of 40 employees.
  • Warner-Lambert is a worldwide company employing approximately 40,000 people.

Sources:

  • PR Newswire: Simulations Plus, Inc. Announces Beta Agreement with Parke-Davis for GastroPlus Simulation Software
  • Simulations Plus, Inc. press release: Simulations Plus Announces Beta Agreement with Parke-Davis for GastroPlus.

Read more